Skip to main content Back to Top
Advertisement

12/2/2019

Levetiracetam Immediate-Release Tablets

Products Affected - Description

    • Roweepra oral immediate release tablet, OWP, 1000 mg, bottle, 120 count, NDC 69102-0103-01
    • Roweepra oral immediate release tablet, OWP, 500 mg, bottle, 120 count, NDC 69102-0104-01
    • Roweepra oral immediate release tablet, OWP, 750 mg, bottle, 120 count, NDC 69102-0102-01
    • Levetiracetam oral immediate release tablet, Accord, 1000 mg, bottle, 60 count, NDC 16729-0067-12 - discontinued
    • Levetiracetam oral immediate release tablet, Accord, 250 mg, bottle, 120 count, NDC 16729-0064-29 - discontinued
    • Levetiracetam oral immediate release tablet, Camber, 1000 mg, bottle, 60 count, NDC 31722-0539-60
    • Levetiracetam oral immediate release tablet, Camber, 250 mg, bottle, 120 count, NDC 31722-0536-12
    • Levetiracetam oral immediate release tablet, Camber, 250 mg, bottle, 500 count, NDC 31722-0536-05
    • Levetiracetam oral immediate release tablet, Camber, 500 mg, bottle, 120 count, NDC 31722-0537-12
    • Levetiracetam oral immediate release tablet, Camber, 500 mg, bottle, 500 count, NDC 31722-0537-05
    • Levetiracetam oral immediate release tablet, Camber, 750 mg, bottle, 120 count, NDC 31722-0538-12
    • Levetiracetam oral immediate release tablet, Camber, 750 mg, bottle, 500 count, NDC 31722-0538-05
    • Levetiracetam oral immediate release tablet, Lupin, 1000 mg, bottle, 60 count, NDC 68180-0115-07
    • Levetiracetam oral immediate release tablet, Lupin, 1000 mg, bottle, 500 count, NDC 68180-0115-02
    • Levetiracetam oral immediate release tablet, Lupin, 500 mg, bottle, 500 count, NDC 68180-0113-02
    • Levetiracetam oral immediate release tablet, Major, 500 mg, bottle, 100 count, NDC 00904-6052-61
    • Levetiracetam oral immediate release tablet, Major, 750 mg, bottle, 100 count, NDC 00904-6053-61
    • Levetiracetam oral immediate release tablet, Mylan, 1000 mg, unit-dose blister pack, 50 count, NDC 51079-0860-06 - discontinued
    • Levetiracetam oral immediate release tablet, Mylan, 250 mg, bottle, 120 count, NDC 00378-5613-78
    • Levetiracetam oral immediate release tablet, Mylan, 250 mg, bottle, 500 count, NDC 00378-5613-05
    • Levetiracetam oral immediate release tablet, Mylan, 250 mg, unit-dose blister pack, 100 count, NDC 51079-0820-20 - discontinued
    • Levetiracetam oral immediate release tablet, Mylan, 500 mg, bottle, 500 count, NDC 00378-5615-05
    • Levetiracetam oral immediate release tablet, Mylan, 750 mg, unit-dose blister pack, 100 count, NDC 51079-0822-20 - discontinued
    • Levetiracetam oral immediate release tablet, Torrent, 1000 mg, bottle, 60 count, NDC 13668-0017-60
    • Levetiracetam oral immediate release tablet, Torrent, 1000 mg, bottle, 500 count, NDC 13668-0017-05
    • Levetiracetam oral immediate release tablet, Torrent, 250 mg, bottle, 120 count, NDC 13668-0014-12
    • Levetiracetam oral immediate release tablet, Torrent, 250 mg, bottle, 250 count, NDC 13668-0014-25
    • Levetiracetam oral immediate release tablet, Torrent, 250 mg, bottle, 500 count, NDC 13668-0014-05
    • Levetiracetam oral immediate release tablet, Torrent, 500 mg, bottle, 120 count, NDC 13668-0015-12
    • Levetiracetam oral immediate release tablet, Torrent, 500 mg, bottle, 250 count, NDC 13668-0015-25
    • Levetiracetam oral immediate release tablet, Torrent, 500 mg, bottle, 500 count, NDC 13668-0015-05
    • Levetiracetam oral immediate release tablet, Torrent, 750 mg, bottle, 120 count, NDC 13668-0016-12
    • Levetiracetam oral immediate release tablet, Torrent, 750 mg, bottle, 250 count, NDC 13668-0016-25
    • Levetiracetam oral immediate release tablet, Torrent, 750 mg, bottle, 500 count, NDC 13668-0016-05

Reason for the Shortage

    • Accord discontinued levetiracetam immediate-release tablets.
    • Aurobindo refuses to provide availability information.
    • Camber did not provide a reason for the shortage.
    • Lupin did not provide a reason for the shortage.
    • Major did not provide a reason for the shortage.
    • Mylan did not provide a reason for the shortage.
    • OWP did not provide a reason for the Roweepra shortage.
    • Torrent did not provide a reason for the shortage.
    • UCB has Keppra immediate-release tablets available.

Available Products

    • Keppra oral immediate release tablet, UCB, 1000 mg, bottle, 60 count, NDC 50474-0597-66
    • Keppra oral immediate release tablet, UCB, 250 mg, bottle, 120 count, NDC 50474-0594-40
    • Keppra oral immediate release tablet, UCB, 500 mg, bottle, 120 count, NDC 50474-0595-40
    • Keppra oral immediate release tablet, UCB, 750 mg, bottle, 120 count, NDC 50474-0597-40
    • Levetiracetam oral immediate release tablet, Lupin, 250 mg, bottle, 90 count, NDC 68180-0112-09
    • Levetiracetam oral immediate release tablet, Lupin, 250 mg, bottle, 120 count, NDC 68180-0112-16
    • Levetiracetam oral immediate release tablet, Lupin, 250 mg, bottle, 500 count, NDC 68180-0112-02
    • Levetiracetam oral immediate release tablet, Lupin, 500 mg, bottle, 90 count, NDC 68180-0113-09
    • Levetiracetam oral immediate release tablet, Lupin, 500 mg, bottle, 120 count, NDC 68180-0113-16
    • Levetiracetam oral immediate release tablet, Lupin, 750 mg, bottle, 90 count, NDC 68180-0114-09
    • Levetiracetam oral immediate release tablet, Lupin, 750 mg, bottle, 500 count, NDC 68180-0114-02
    • Levetiracetam oral immediate release tablet, Major, 250 mg, bottle, 100 count, NDC 00904-6051-61
    • Levetiracetam oral immediate release tablet, Mylan, 1000 mg, bottle, 60 count, NDC 00378-5619-91
    • Levetiracetam oral immediate release tablet, Mylan, 500 mg, bottle, 120 count, NDC 00378-5615-78
    • Levetiracetam oral immediate release tablet, Mylan, 500 mg, unit-dose blister pack, 100 count, NDC 51079-0821-20
    • Levetiracetam oral immediate release tablet, Mylan, 750 mg, bottle, 120 count, NDC 00378-5617-78
    • Levetiracetam oral immediate release tablet, Mylan, 750 mg, bottle, 500 count, NDC 00378-5617-05

Estimated Resupply Dates

    • Camber has levetiracetam immediate-release tablets on allocation to contracted customers.
    • Lupin has levetiracetam 500 mg immediate-release tablets in 500 count on back order and the company cannot estimate a release date. The 1,000 mg immediate-release tablets in 60 and 500 count are on back order and the company cannot estimate a release date.
    • Major has levetiracetam 500 mg and 750 mg immediate-release tablets on back order and the company estimates a release date of late-November 2019.
    • Mylan has levetiracetam 250 mg immediate-release tablets in 120 and 500 count and 500 mg immediate-release tablets in 500 count on back order and the company estimates a release date of mid-February 2020.
    • OWP has Roweepra immediate-release tablets on back order and the company cannot estimate a release date.
    • Torrent has levetiracetam immediate-release tablets on allocation.

Updated

Updated December 2, 2019 by Anthony Trovato, PharmD, BCPS. Created February 22, 2019 by Leslie Jensen, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins